114 related articles for article (PubMed ID: 33365366)
21. Investigation of gold nanoparticle effects in brachytherapy by an electron emitter ophthalmic plaque.
Hashemi S; Aghamiri MR; Kahani M; Jaberi R
Int J Nanomedicine; 2019; 14():4157-4165. PubMed ID: 31239674
[No Abstract] [Full Text] [Related]
22. Monte Carlo Estimation of Absorbed Dose Distributions Obtained from Heterogeneous
Zaragoza FJ; Eichmann M; Flühs D; Sauerwein W; Brualla L
Ocul Oncol Pathol; 2017 Sep; 3(3):204-209. PubMed ID: 29071271
[TBL] [Abstract][Full Text] [Related]
23. [A procedure for the determination of dose performance of radioactive eye applicators (106-Ru/106-Rh) and their significance for indications and treatment in malignant choroid melanomas].
Menapace R; Binder W
Klin Monbl Augenheilkd; 1985 Nov; 187(5):451-4. PubMed ID: 4087812
[TBL] [Abstract][Full Text] [Related]
24. Clinical quality assurance for 106Ru ophthalmic applicators.
Kaulich TW; Zurheide J; Haug T; Nüsslin F; Bamberg M
Radiother Oncol; 2005 Jul; 76(1):86-92. PubMed ID: 15972240
[TBL] [Abstract][Full Text] [Related]
25. Dosimetry of beta-ray ophthalmic applicators: comparison of different measurement methods.
Soares CG; Vynckier S; Järvinen H; Cross WG; Sipilä P; Flühs D; Schaeken B; Mourtada FA; Bass GA; Williams TT
Med Phys; 2001 Jul; 28(7):1373-84. PubMed ID: 11488568
[TBL] [Abstract][Full Text] [Related]
26. Monte Carlo simulation of COMS ophthalmic applicators loaded with Bebig I25.S16 seeds and comparison with planning system predictions.
Miras H; Terrón JA; Lallena AM
Phys Med; 2013 Nov; 29(6):670-6. PubMed ID: 22858007
[TBL] [Abstract][Full Text] [Related]
27. Air core detectors for Cerenkov-free scintillation dosimetry of brachytherapy β-sources.
Eichmann M; Thomann B
Med Phys; 2017 Sep; 44(9):4900-4909. PubMed ID: 28548280
[TBL] [Abstract][Full Text] [Related]
28. Dosimetry of ruthenium-106 eye applicators.
Davelaar J; Schaling DF; Hennen LA; Broerse JJ
Med Phys; 1992; 19(3):691-4. PubMed ID: 1508109
[TBL] [Abstract][Full Text] [Related]
29. Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of ≥5.5 mm.
Filì M; Trocme E; Bergman L; See TRO; André H; Bartuma K; Girnita L; All-Eriksson C; Seregard S; Stålhammar G
Br J Ophthalmol; 2020 Jan; 104(1):26-32. PubMed ID: 30910871
[TBL] [Abstract][Full Text] [Related]
30. Dose Distributions and Treatment Margins in Ocular Brachytherapy with 106Ru Eye Plaques.
Stöckel E; Eichmann M; Flühs D; Sommer H; Biewald E; Bornfeld N; Spaan B; Sauerwein W
Ocul Oncol Pathol; 2018 Sep; 4(2):122-128. PubMed ID: 30320093
[TBL] [Abstract][Full Text] [Related]
31. Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling.
Browne AW; Dandapani SV; Jennelle R; Stevanovic M; Lee TC; Murphree AL; Kampp TD; Astrahan MA; Kim JW; Berry JL
Brachytherapy; 2015; 14(5):718-25. PubMed ID: 26073224
[TBL] [Abstract][Full Text] [Related]
32. The design and the dosimetry of bi-nuclide radioactive ophthalmic applicators.
Flühs D; Anastassiou G; Wening J; Sauerwein W; Bornfeld N
Med Phys; 2004 Jun; 31(6):1481-8. PubMed ID: 15259651
[TBL] [Abstract][Full Text] [Related]
33. Calculating lens dose and surface dose rates from 90Sr ophthalmic applicators using Monte Carlo modeling.
Gleckler M; Valentine JD; Silberstein EB
Med Phys; 1998 Jan; 25(1):29-36. PubMed ID: 9472823
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma.
Lommatzsch PK; Werschnik C; Schuster E
Graefes Arch Clin Exp Ophthalmol; 2000 Feb; 238(2):129-37. PubMed ID: 10766281
[TBL] [Abstract][Full Text] [Related]
35. The determination of dose characteristics of ruthenium ophthalmic applicators using radiochromic film.
Taccini G; Cavagnetto F; Coscia G; Garelli S; Pilot A
Med Phys; 1997 Dec; 24(12):2034-7. PubMed ID: 9434987
[TBL] [Abstract][Full Text] [Related]
36. Monte Carlo dosimetry for 103Pd, 125I, and 131Cs ocular brachytherapy with various plaque models using an eye phantom.
Lesperance M; Martinov M; Thomson RM
Med Phys; 2014 Mar; 41(3):031706. PubMed ID: 24593710
[TBL] [Abstract][Full Text] [Related]
37. I-125 ROPES eye plaque dosimetry: validation of a commercial 3D ophthalmic brachytherapy treatment planning system and independent dose calculation software with GafChromic® EBT3 films.
Poder J; Corde S
Med Phys; 2013 Dec; 40(12):121709. PubMed ID: 24320495
[TBL] [Abstract][Full Text] [Related]
38. Mathematical solutions of the TG-43 geometry function for curved line, ring, disk, sphere, dome and annulus sources, and applications for quality assurance.
Deufel C; Furutani KM; Thomson RM; Antolak JA
Phys Med Biol; 2011 Aug; 56(16):5429-44. PubMed ID: 21804178
[TBL] [Abstract][Full Text] [Related]
39. Dosimetry of (125)I and (103)Pd COMS eye plaques for intraocular tumors: report of Task Group 129 by the AAPM and ABS.
Chiu-Tsao ST; Astrahan MA; Finger PT; Followill DS; Meigooni AS; Melhus CS; Mourtada F; Napolitano ME; Nath R; Rivard MJ; Rogers DW; Thomson RM
Med Phys; 2012 Oct; 39(10):6161-84. PubMed ID: 23039655
[TBL] [Abstract][Full Text] [Related]
40. A novel quality assurance system for eye plaque brachytherapy.
Kejda A; Cutajar D; Weaver M; Petasecca M; Rosenfeld A
Australas Phys Eng Sci Med; 2019 Dec; 42(4):1109-1115. PubMed ID: 31728937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
